NCT03282253

Brief Summary

In this study, the investgatiors aimed to investigate the associations between serum levels of stearoyl-CoA desaturase-1（SCD-1） and the disease severity as well as the presence of adverse clinical events, such as local complications, organ failure, mortality and so on.In this prospective study, participants were divided into two groups based on serum SCD-1 concentration on admission and prospectively observe the disease severity and clinical outcomes of them.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
216

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2018

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 12, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 13, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2019

Completed
Last Updated

November 27, 2017

Status Verified

November 1, 2017

Enrollment Period

12 months

First QC Date

September 12, 2017

Last Update Submit

November 23, 2017

Conditions

Acute PancreatitisOrgan Failure, Multiple

Outcome Measures

Primary Outcomes (1)

  • the incidence rate of infected pancreatic necrosis

    2-4 week after disease onset

Secondary Outcomes (2)

  • the incidence rate of organ failure

    1-2 week after disease onset

  • the incidence rate of local complications

    1-2 week after disease onset

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with the diagnosis of acute pancreatitis (Atlanta standard), abdominal pain occurred within one week of admission; we intended to include the severer cases (APACHEII score is more than 8 and Ranson score is greater than 3).

You may qualify if:

  • Diagnosis of acute pancreatitis (Atlanta standard), abdominal pain occurred within one week of admission;
  • APACHEII score is more than 8 and Ranson score is greater than 3;
  • Age 18-75;
  • Obtaining informed consent.

You may not qualify if:

  • Pregnancy pancreatitis;
  • Patients with the following disease history: severe cardiac, pulmonary, renal, liver function insufficiency or immunodeficiency disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

PancreatitisMultiple Organ Failure

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesShockPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Department of Surgical Intensive Care Unit

Study Record Dates

First Submitted

September 12, 2017

First Posted

September 13, 2017

Study Start

January 1, 2018

Primary Completion

December 30, 2018

Study Completion

June 30, 2019

Last Updated

November 27, 2017

Record last verified: 2017-11